Vaxcyte Inc. (PCVX)

The total asset value of Vaxcyte Inc. (PCVX) stood at $ 1,582 Mln as on 30-Sep-23

The share price of Vaxcyte Inc. (PCVX) is $50.08 (NASDAQ) as of 28-Nov-2023 16:00 EST. Vaxcyte Inc. (PCVX) has given a return of 13.07% in the last 3 years.

Vaxcyte Inc. (PCVX) has a market capitalisation of $ 4,663 Mln as on 24-Nov-2023. As per Value Research classification, it is a Small Cap company.

The P/B ratio of Vaxcyte Inc. (PCVX) is 10.05 times as on 24-Nov-2023, a 2.96% premium to its peers’ median range of 2.54 times.

Since, TTM earnings of Vaxcyte Inc. (PCVX) is negative, P/E ratio is not available.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Vaxcyte Inc. (PCVX) and enter the required number of quantities and click on buy to purchase the shares of Vaxcyte Inc. (PCVX).

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against these emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

The CEO & director of Mr. Grant E. Pickering M.B.A.. is Vaxcyte Inc. (PCVX), and CFO & Sr. VP is Mr. Andrew L. Guggenhime M.B.A..

The promoters of Vaxcyte Inc. (PCVX) have pledged 0% of the total equity as on Jun-23.

Some of the close peers are:

No, TTM profit after tax of Vaxcyte Inc. (PCVX) was $-60 Mln.